Practices of excellent companies in the drug industry

Abstract

Examines excellence in three major pharmaceutical companies: Merck, Lilly, and Glaxo. Provides an overview of recent trends in the health care industry. Shows that, although all three companies are facing tough competition and strict cost‐containment pressures, they continue to develop innovative strategies for increasing the quality of their product offering. Analyses Merck’s recent acquisition of Medco and its implications; also highlights Merck’s “Vital Interests” programme. Discusses Lilly’s recent purchase of PCS from McKesson Drug and Lilly’s recent efforts to concentrate on its core business. Introduces Helix, Glaxo’s new computer network for pharmacists and explains the benefits of this unique service, both to its users and the sponsor.

Citation

Pringle, F. and Kleiner, B.H. (1997), "Practices of excellent companies in the drug industry", International Journal of Health Care Quality Assurance, Vol. 10 No. 1, pp. 31-34. https://doi.org/10.1108/09526869710159615